Rhenman & Partners Asset Management AB Buys 40,000 Shares of Abbott Laboratories $ABT

Rhenman & Partners Asset Management AB raised its stake in Abbott Laboratories (NYSE:ABT) by 68.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 98,500 shares of the healthcare product maker’s stock after acquiring an additional 40,000 shares during the quarter. Abbott Laboratories makes up 1.5% of Rhenman & Partners Asset Management AB’s holdings, making the stock its 29th biggest position. Rhenman & Partners Asset Management AB’s holdings in Abbott Laboratories were worth $13,193,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently modified their holdings of ABT. Grantham Mayo Van Otterloo & Co. LLC lifted its stake in Abbott Laboratories by 4.6% in the third quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 8,176,484 shares of the healthcare product maker’s stock valued at $1,095,158,000 after purchasing an additional 361,946 shares during the last quarter. First Trust Advisors LP increased its position in Abbott Laboratories by 26.5% in the third quarter. First Trust Advisors LP now owns 3,874,127 shares of the healthcare product maker’s stock worth $518,901,000 after buying an additional 810,684 shares during the last quarter. Ramirez Asset Management Inc. raised its stake in shares of Abbott Laboratories by 6.0% in the third quarter. Ramirez Asset Management Inc. now owns 22,319 shares of the healthcare product maker’s stock valued at $2,989,000 after buying an additional 1,270 shares during the period. Foster Dykema Cabot & Partners LLC lifted its position in shares of Abbott Laboratories by 16.6% during the 3rd quarter. Foster Dykema Cabot & Partners LLC now owns 8,108 shares of the healthcare product maker’s stock valued at $1,086,000 after buying an additional 1,153 shares during the last quarter. Finally, Chapman Financial Group LLC bought a new position in shares of Abbott Laboratories during the 3rd quarter worth $515,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Performance

NYSE ABT opened at $109.74 on Friday. The company has a market capitalization of $190.69 billion, a P/E ratio of 29.50, a P/E/G ratio of 1.74 and a beta of 0.74. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58. Abbott Laboratories has a 52-week low of $105.27 and a 52-week high of $139.15. The company has a fifty day moving average of $116.09 and a 200-day moving average of $124.63.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.50. The firm had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period in the prior year, the business earned $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, equities research analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 67.74%.

Insider Activity

In related news, SVP Eric Shroff sold 709 shares of Abbott Laboratories stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $81,946.22. Following the transaction, the senior vice president owned 39,164 shares in the company, valued at $4,526,575.12. This trade represents a 1.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Daniel J. Starks purchased 10,000 shares of the business’s stock in a transaction on Wednesday, February 4th. The shares were acquired at an average price of $108.73 per share, with a total value of $1,087,300.00. Following the completion of the transaction, the director owned 6,738,817 shares of the company’s stock, valued at approximately $732,711,572.41. This trade represents a 0.15% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders sold 3,055 shares of company stock valued at $353,097. Insiders own 0.46% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on ABT shares. Leerink Partners lowered their price objective on Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating on the stock in a research note on Friday, January 30th. William Blair raised shares of Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, November 20th. The Goldman Sachs Group cut their price objective on shares of Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a report on Friday, January 23rd. Evercore dropped their target price on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Finally, Weiss Ratings lowered Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 26th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $137.05.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.